Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy: (Trends in Biochemical Sciences 43, 1014-1032; 2018).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).International journal of molecular medicine · 2023
   Pooled it
2. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
   Trial
3. Immune checkpoint inhibitors (ICIs) for second-line retreatment in esophageal cancer progressing after first-line immunotherapy: a single-center retrospective cohort study.Journal of thoracic disease · 2026
   Article
4. The Prognostic Value of EDRIC and Its Association With Radiation-Induced Lymphopenia in Patients With Esophageal Cancer Undergoing Radical Radiotherapy: A Single-Center Chinese Study.The Kaohsiung journal of medical sciences · 2026
   Article
5. Deciphering the regulatory landscape of enhancer RNAs in health and disease.Signal transduction and targeted therapy · 2026
   Review
6. Dietary ω-3 polyunsaturated fatty acids (PUFAs) reduce cholesterol-driven non-small cell lung cancer (NSCLC) progression in mouse models of disease.Communications medicine · 2025
   Article
7. The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence.Oncology reports · 2024
   Article
8. Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer.Science advances · 2023
   Article
9. Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target.Proceedings of the National Academy of Sciences of the United States of America · 2023
   Article
10. Research progress on immunotherapy in triple‑negative breast cancer (Review).International journal of oncology · 2022
    Review
11. Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma.The Journal of international medical research · 2021
    Article
12. Impact of inflammation and immunotherapy in renal cell carcinoma.Oncology letters · 2020
    Review
13. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.Nature cell biology · 2020
    Article
14. PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.Oncology letters · 2020
    Article

Corrections and comments

• Erratum for
  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.2018

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.